Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia Article

Li, ZH, Qiao, Y, Liu, B et al. (2005). Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia . CLINICAL CANCER RESEARCH, 11(12), 4460-4468. 10.1158/1078-0432.CCR-05-0250

Open Access

cited authors

  • Li, ZH; Qiao, Y; Liu, B; Laska, EJ; Chakravarthi, P; Kulko, JM; Bona, RD; Fang, M; Hegde, U; Moyo, V; Tannenbaum, SH; Ménoret, A; Gaffney, J; Glynn, L; Runowicz, CD; Srivastava, PK

sustainable development goals

authors

publication date

  • June 15, 2005

published in

keywords

  • BONE-MARROW TRANSPLANTATION
  • CANCER
  • CHRONIC MYELOID-LEUKEMIA
  • CLINICAL RESISTANCE
  • DENDRITIC CELLS
  • IMMUNOTHERAPY
  • IN-VITRO
  • Life Sciences & Biomedicine
  • Oncology
  • PEPTIDE COMPLEXES
  • RESPONSES
  • Science & Technology
  • VACCINATION

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

start page

  • 4460

end page

  • 4468

volume

  • 11

issue

  • 12